Arrowhead Pharmaceuticals Inc. (ARWR)
NASDAQ · Healthcare
Arrowhead Pharmaceuticals Inc. EBITDA 2011–2025
Arrowhead Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2011 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Arrowhead Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was -135.4 M, a 134.99% decrease year-over-year.
- Arrowhead Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2026 was 138.5 M, a 123.75% decrease year-over-year.
- Arrowhead Pharmaceuticals Inc. annual ebitda for 2025 was 120.5 M, a 120.64% decrease from 2024.
- Arrowhead Pharmaceuticals Inc. annual ebitda for 2024 was -584.2 M, a 200.66% increase from 2023.
- Arrowhead Pharmaceuticals Inc. annual ebitda for 2023 was -194.3 M, a 14.43% increase from 2022.
- Arrowhead Pharmaceuticals Inc. annual ebitda for 2022 was -169.8 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Arrowhead Pharmaceuticals Inc. EBITDA — FAQ
Arrowhead Pharmaceuticals Inc. (ARWR) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ARWR's ebitda history?
The chart and table above show Arrowhead Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.